Jack W.  Schuler net worth and biography

Jack Schuler Biography and Net Worth

Jack Schuler is an independent director of Accelerate Diagnostics, an in vitro diagnostics company providing lifesaving solutions for serious infections.

He also serves as a director for Biodesix, Inc. and Minute Molecular Diagnostics, Inc., and he has previously served on the boards of directors for Ventana Medical Systems, Medtronic, Stericycle, and Quidel Corporation.

Schuler has a career spanning 30 years in the pharmaceutical industry, including a variety of executive positions at Abbott Laboratories, most recently as president and chief operating officer. He is also a founding partner of private equity firm Crabtree Partners.

Additionally, he is the co-founder and chairman of The Schuler Scholar Program, which assists high-achieving and underrepresented students in gaining access to selective universities. Schuler founded the program in 2001 with his daughter, Natasha.

Schuler earned his B.S. in mechanical engineering from Tufts University and his M.B.A. from Stanford University’s Graduate School of Business Administration. He resides in Lake Bluff, Illinois with his wife, Renate. 

What is Jack W. Schuler's net worth?

The estimated net worth of Jack W. Schuler is at least $22.98 million as of November 20th, 2024. Mr. Schuler owns 31,094,935 shares of Accelerate Diagnostics stock worth more than $22,979,157 as of March 31st. This net worth evaluation does not reflect any other assets that Mr. Schuler may own. Learn More about Jack W. Schuler's net worth.

How do I contact Jack W. Schuler?

The corporate mailing address for Mr. Schuler and other Accelerate Diagnostics executives is 3950 South Country Club Suite 470, Tucson AZ, 85714. Accelerate Diagnostics can also be reached via phone at (520) 365-3100 and via email at investors@axdx.com. Learn More on Jack W. Schuler's contact information.

Has Jack W. Schuler been buying or selling shares of Accelerate Diagnostics?

Jack W. Schuler has not been actively trading shares of Accelerate Diagnostics over the course of the past ninety days. Most recently, on Tuesday, January 18th, Jack W. Schuler bought 4,191 shares of Accelerate Diagnostics stock. The stock was acquired at an average cost of $39.40 per share, with a total value of $165,125.40. Learn More on Jack W. Schuler's trading history.

Who are Accelerate Diagnostics' active insiders?

Accelerate Diagnostics' insider roster includes Hany Massarany (Director), Jack Phillips (CEO), Ron Price (Insider), Steven Reichling (CFO), and Jack Schuler (Director). Learn More on Accelerate Diagnostics' active insiders.

Are insiders buying or selling shares of Accelerate Diagnostics?

During the last twelve months, Accelerate Diagnostics insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $314,000.00. During the last twelve months, insiders at the medical research company sold shares 8 times. They sold a total of 98,321 shares worth more than $83,157.63. The most recent insider tranaction occured on February, 26th when CFO David Patience sold 535 shares worth more than $583.15. Insiders at Accelerate Diagnostics own 43.6% of the company. Learn More about insider trades at Accelerate Diagnostics.

Information on this page was last updated on 2/26/2025.

Jack W. Schuler Insider Trading History at Accelerate Diagnostics

Jack W. Schuler Buying and Selling Activity at Accelerate Diagnostics

This chart shows Jack W Schuler's buying and selling at Accelerate Diagnostics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Accelerate Diagnostics Company Overview

Accelerate Diagnostics logo
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Read More

Today's Range

Now: $0.70
Low: $0.70
High: $0.75

50 Day Range

MA: $1.13
Low: $0.70
High: $1.39

2 Week Range

Now: $0.70
Low: $0.69
High: $2.09

Volume

51,959 shs

Average Volume

60,190 shs

Market Capitalization

$17.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55